Analyst Price Target is $8.63
▲ +98.73% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lumos Pharma in the last 3 months. The average price target is $8.63, with a high forecast of $13.00 and a low forecast of $4.25. The average price target represents a 98.73% upside from the last price of $4.34.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Lumos Pharma. This rating has held steady since November 2023, when it changed from a Moderate Buy consensus rating.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.
Read More